Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dacarbazine, pazopanib, gemcitabine + docetaxel, doxorubicin, ifosfamide
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen consisting of six anticancer agents: - **Dacarbazine** is an alkylating agent that works by methylating DNA and inhibiting DNA synthesis. - **Pazopanib** is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs) and other kinases to inhibit angiogenesis. - **Gemcitabine** is a nucleoside analog that inhibits DNA synthesis. - **Docetaxel** is a taxane that stabilizes microtubules and prevents cell division. - **Doxorubicin** is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II. - **Ifosfamide** is an alkylating agent causing cross-linking of DNA strands. This multi-agent regimen combines drugs with different mechanisms of action for the treatment of advanced or refractory soft tissue sarcoma and other solid tumors. The combination of gemcitabine plus docetaxel has demonstrated efficacy in soft tissue sarcoma after failure with doxorubicin/ifosfamide regimens[1][7]. Each drug contributes unique antitumor activity through distinct molecular targets.
- Brand names
- TaxotereAdriamycinIfexDTIC-Dome
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RNR (Ribonucleotide reductase)TOP2A (DNA topoisomerase II)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on dacarbazine, pazopanib, gemcitabine + docetaxel, doxorubicin, ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dacarbazine, pazopanib, gemcitabine + docetaxel, doxorubicin, ifosfamide.